• AVONEX) in relapsing forms of multiple sclerosis. (nih.gov)
  • Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). (physiciansweekly.com)
  • Interferon beta products currently licensed in the UK are Avonex , Rebif (interferon beta-1a), Betaferon , Extavia (interferon beta-1b) and the new product Plegridy (peginterferon beta-1a). (mims.co.uk)
  • Many patients report influenza-like symptoms hours after taking interferon beta that usually improve within 24 hours, being such symptoms related to the temporary increase of cytokines. (wikipedia.org)
  • Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. (nih.gov)
  • Once weekly intramuscular IFNbeta-1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long-term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions. (nih.gov)
  • The pivotal intramuscular IFN β-1a phase III trial published in 1996 was the first to demonstrate that a DMT could reduce accumulation of sustained disability in MS. Patient adherence to treatment is higher with intramuscular IFN β-1a, given once weekly, than with subcutaneous formulations requiring multiple injections per week. (physiciansweekly.com)
  • In the present population-based study, we used routinely collected healthcare data in the Campania Region of Italy, from 2015 to 2017, to describe the use of different Interferon Beta formulations and to evaluate possible differences, assuming that dosing, frequency of administration, subcutaneous/intramuscular injection, and/or associated devices can affect persistence, adherence, healthcare resource utilisation and costs. (biomedcentral.com)
  • Interferon beta-1a intramuscular injection comes as a solution (liquid) in prefilled injection syringes and in a prefilled automatic injection pen. (medlineplus.gov)
  • Inject interferon beta-1a intramuscular at around the same time of day on your injection days. (medlineplus.gov)
  • Before you use interferon beta-1a intramuscular for the first time, you or the person who will be giving the injections should also read the manufacturer's information for the patient that comes with it. (medlineplus.gov)
  • Talk to your doctor or pharmacist about where on your body you should inject interferon beta-1a intramuscular. (medlineplus.gov)
  • If you are using a prefilled syringe, you can inject interferon beta-1a intramuscular in your upper arms or thighs. (medlineplus.gov)
  • If you are using a prefilled autoinjection pen, you can inject interferon beta-1a intramuscular in the outer surface of your upper thighs. (medlineplus.gov)
  • Two hours after you inject interferon beta-1 intramuscular, you should check the injection site for a skin reaction such as redness, swelling, or tenderness. (medlineplus.gov)
  • METHODS In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body weight of ≤40 kg) or intramuscular interferon beta-1a at a dose of 30 μg per week for up to 2 years. (elsevierpure.com)
  • A recent Cochrane systematic review demonstrated that intramuscular interferon beta 1a (IFN-ß-1a-IM) was inferior to the other beta interferons (IFN-ßs) for multiple sclerosis (MS). As a result, CONITEC commissioned an analysis to review possible disinvestment within SUS. (bvsalud.org)
  • Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments. (wikipedia.org)
  • Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a. (elsevierpure.com)
  • Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. (nih.gov)
  • [ 1 , 2 ] Approximately 15% of patients with MS experience a primary progressive course from onset, either without preceding relapses (known as primary progressive multiple sclerosis [PPMS]) or with superimposed neurologic events, known as progressive relapsing MS. (medscape.com)
  • Medications for multiple sclerosis (MS) include a wide variety of drugs to modify the course of the disease, treat relapses, or help manage symptoms. (medicalnewstoday.com)
  • DMTs are not a cure for MS, but they may help slow the progression of the disease and reduce the number and severity of relapses, according to the Multiple Sclerosis Association of America (MSAA) . (medicalnewstoday.com)
  • Natalizumab reduces relapses in patients with active multiple sclerosis (MS), but recent studies report severe worsening of MS after suspension of treatment, as a consequence of the rebound effect. (thieme-connect.de)
  • Treatment and management of multiple sclerosis should be targeted toward relieving symptoms of the disease, treating acute exacerbations, shortening the duration of an acute relapse, reducing frequency of relapses, and preventing disease progression. (medscape.com)
  • Most people with multiple sclerosis have periods of relatively good health (remissions) alternating with periods of worsening symptoms (flare-ups or relapses). (msdmanuals.com)
  • We found that the most significant differentially methylated sites had a remarkable enrichment in type I interferon (IFN) pathway genes. (frontiersin.org)
  • stimulation in primary Sjogren's syndrome patients associates with type I interferon signature. (uib.no)
  • DYT-PRKRA Mutation P222L Enhances PACT's Stimulatory Activity on Type I Interferon Induction. (nih.gov)
  • The interferon-α/β receptor (IFNAR) is a virtually ubiquitous membrane receptor which binds endogenous type I interferon (IFN) cytokines. (wikidoc.org)
  • Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. (wikipedia.org)
  • Despite the availability of several disease-modifying treatments for relapsing forms of multiple sclerosis, patients often continue to have clinical and subclinical disease activity, and neurologic disability continues to accrue. (synergy-munich.de)
  • It is indicated for relapsing forms of multiple sclerosis. (medscape.com)
  • It is known that 30% of MS patients are non-responsive to Beta interferon. (wikipedia.org)
  • UK neurologists have been slow to prescribe beta interferon and other potentially disease-modifying drugs for multiple sclerosis (MS). We have been constrained by our notorious conservatism, which is in part based on our demand for good evidence before changing practice, particularly when it comes to very expensive therapeutic interventions such as beta interferon. (bmj.com)
  • But there has been another constraint - the UK National Health Service (NHS) has a centralized command and control system (which I personally rather approve of) that would not sanction the prescription of beta interferon because of its very high cost. (bmj.com)
  • Beta interferon drugs help regulate the immune cells. (medicalnewstoday.com)
  • Disease-modifying therapies, including beta-interferon (IFN-b), are increasingly used to minimise relapse frequency in the majority of patients who present with a relapsing-remitting disease pattern. (rcpe.ac.uk)
  • Interferon beta inhibits the expression of pro-inflammatory cytokines, including interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha and TNF-beta, interferon gamma (IFN-γ), and IL-6. (medscape.com)
  • They add that we should consider ocrelizumab in primary progressive MS and beta interferon for secondary progressive MS. (medscape.com)
  • On the basis of results from previous phase 2 studies of the chimeric anti-CD20 antibody rituximab and ocrelizumab, we undertook two phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group trials (OPERA I and OPERA II) to investigate the efficacy and safety of ocrelizumab, as compared with subcutaneous interferon beta-1a, in patients with relapsing multiple sclerosis. (synergy-munich.de)
  • Side effects are often onerous enough that many patients ultimately discontinue taking Interferons (or glatiramer acetate, a comparable disease-modifying therapies requiring regular injections). (wikipedia.org)
  • For patients with ON whose brain lesions on MRI indicate a high risk of developing clinically definite MS, treatment with immunomodulators (eg, interferon [INF] beta-1a, INF beta-1b, glatiramer acetate) may be considered. (medscape.com)
  • In patients with clinically isolated syndrome and positive MRI, they recommend starting with interferon or glatiramer acetate. (medscape.com)
  • Interferon beta-1a is in a class of medications called immunomodulators. (medlineplus.gov)
  • Interferon Beta formulations presented with different prescription patterns, persistence, adherence, healthcare resource utilisation and costs, with Rebif® being used in younger patients and with less MS-related hospital admissions. (biomedcentral.com)
  • Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the 'old' therapies? (bmj.com)
  • Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. (uni-wuerzburg.de)
  • These systemic Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. (uni-wuerzburg.de)
  • Children and teens with multiple sclerosis are treated with the same therapies as adults, but they are considered "off label" for treating children, (not an FDA approved the use of the drug, but it is/may be effective for some people with the condition). (medicinenet.com)
  • Background: Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system which responds to therapies targeting circulating immune cells. (edu.au)
  • This is why interferon therapies for viral infections are typically a last resort - the potential for dire side effects. (hdkino.org)
  • The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology published recent guidelines on the treatment of multiple sclerosis (MS) in the European Journal of Neurology . (medscape.com)
  • Then there was an interesting study published in JAMA Neurology , [ 10 ] in which researchers looked at rituximab and other treatments of relapsing-remitting MS in patients identified from the Sweden Multiple Sclerosis Registry. (medscape.com)
  • Dr. Sarah Hopkins is an assistant professor of clinical neurology and section head for multiple sclerosis and neuro-inflammatory disorders in the division of neurology at Children's Hospital of Philadelphia. (cdc.gov)
  • In conclusion, we think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. (uni-wuerzburg.de)
  • Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. (uni-wuerzburg.de)
  • Background: Interferon beta (IFNB) is available in parenteral formulations for treatment of multiple sclerosis (MS). The purpose of this study was to evaluate safety, tolerability and effects on MRI lesions of three different doses of oral IFNB-1a compared with placebo over six months in relapsing-remitting (RR) MS patients. (amsterdamumc.org)
  • Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS. Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis and in reducing the accumulation of brain lesions, which is measured using gadolinium-enhanced magnetic resonance imaging (MRI). (wikipedia.org)
  • CONCLUSIONS Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI over a 2-year period than interferon beta-1a but was associated with a higher rate of serious adverse events. (elsevierpure.com)
  • To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. (biomedcentral.com)
  • CONCLUSIONS: Sarcoidosis should be considered in the differential diagnosis of a patient who develops clinical or radiological pulmonary disease while undergoing interferon therapy. (ox.ac.uk)
  • The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. (wikipedia.org)
  • Graves' disease (GD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are complex autoimmune diseases sharing common clinical, genetic and pathogenetic features. (frontiersin.org)
  • Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. (gencat.cat)
  • The primary endpoint was conversion to clinically definite multiple sclerosis due to clinical relapse. (ox.ac.uk)
  • The modest correlation between new lesion formation and brain volume decrease suggests that inflammatory and neurodegenerative processes are, at least partly, dissociated from the earliest clinical stage of multiple sclerosis onwards. (ox.ac.uk)
  • In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS. (sciencedaily.com)
  • 16 Runia T.F., van Pelt-Gravesteijn E.D., Hintzen R.Q. Recent gains in clinical multiple sclerosis research review. (thieme-connect.de)
  • Interferon beta-1b was the first medication approved by the FDA for MS. It is approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. (medscape.com)
  • Interferon beta-1a is approved for the treatment of patients with relapsing forms of MS. It helps to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. (medscape.com)
  • LI, D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. (bvsalud.org)
  • Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. (ox.ac.uk)
  • BACKGROUND: In patients who present with clinically isolated syndromes suggestive of multiple sclerosis, interferon beta-1a is effective in delaying evolution to clinically definite disease and in reducing MRI-measured disease activity. (ox.ac.uk)
  • Neurologists managing patients with multiple sclerosis should be aware of this association between interferon-β and sarcoidosis and promptly refer patients developing respiratory symptoms for further investigation. (ox.ac.uk)
  • Another common transient secondary effect with interferon-beta is a functional deterioration of already existing symptoms of the disease. (wikipedia.org)
  • It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis. (medlineplus.gov)
  • Interferon beta-1a controls the symptoms of MS but does not cure it. (medlineplus.gov)
  • In relapsing multiple sclerosis (PRMS) patients experience increasing symptoms over time and intermittent episodes of remission. (medicinenet.com)
  • Signs and symptoms of multiple sclerosis are variable and depend on the area of the destruction of the myelin protecting the brain and spinal cord nerves. (medicinenet.com)
  • The MHRA has reminded healthcare professionals to be vigilant for signs or symptoms of thrombotic microangiopathy and nephrotic syndrome in patients with multiple sclerosis receiving interferon beta. (mims.co.uk)
  • interferon naturally occurring in the body is responsible for all flu-like symptoms to begin with, whether you have the coronavirus or a common cold . (hdkino.org)
  • So, if someone is already on a ventilator and symptoms are about to overwhelm them, giving them an interferon-based medicine could be catastrophic. (hdkino.org)
  • In most people with multiple sclerosis, periods of relatively good health alternate with episodes of worsening symptoms, but over time, multiple sclerosis gradually worsens. (msdmanuals.com)
  • Usually, doctors diagnose multiple sclerosis based on symptoms and results of a physical examination and magnetic resonance imaging. (msdmanuals.com)
  • Alzheimer's disease and multiple sclerosis are neurodegenerative disorders with expensive and complex treatments aimed at reducing the progression of symptoms. (bvsalud.org)
  • Evidence linking sunlight, vitamin D, and the risk of multiple sclerosis and type 1 diabetes is summarized to develop the thesis that vitamin D is the environmental factor that most strongly influences autoimmune disease development. (frontiersin.org)
  • Pediatric optic neuritis and risk of multiple sclerosis: Meta-analysis of observational studies. (medscape.com)
  • Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: a meta-analysis of 6977 subjects. (cdc.gov)
  • Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis. (cdc.gov)
  • abstract = "BACKGROUND Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. (elsevierpure.com)
  • Interferons, a subclass of cytokines, are produced in the body during illnesses such as influenza in order to help fight the infection. (wikipedia.org)
  • Interferon beta inhibits the expression of proinflammatory cytokines, including interferon gamma (IFN-γ), which is believed to be a major factor responsible for triggering the autoimmune reaction leading to MS. (medscape.com)
  • During a CIS, there is a subacute attack suggestive of demyelination but the patient does not fulfill the criteria for diagnosis of multiple sclerosis. (wikipedia.org)
  • These criteria allow the diagnosis of multiple sclerosis to be made at the clinically isolated syndrome stage provided certain criteria are met on a single magnetic resonance brain scan. (rcpe.ac.uk)
  • Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta-1b. (wikipedia.org)
  • Remitting multiple sclerosis (RRMS) is the most common form of MS . Remission may last for weeks to years. (medicinenet.com)
  • ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFNβ) and natalizumab have been pooled and characterized through collaboration within a European consortium. (gencat.cat)
  • Natalizumab for multiple sclerosis? (bmj.com)
  • 15 Horga A., Tintoré M. Natalizumab for relapsing-remitting multiple sclerosis. (thieme-connect.de)
  • 18 Kleinschmidt-DeMasters B.K., Miravalle A., Schowinsky J., Corboy J., Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. (thieme-connect.de)
  • Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. (qxmd.com)
  • We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. (qxmd.com)
  • Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks. (qxmd.com)
  • Our study aimed to evaluate the persistence to treatment with interferon beta-1b (INFβ-1b) in a group of 113 patients with relapsing-remitting and secondary progressive multiple sclerosis over a 19-year follow-up period. (farmaciajournal.com)
  • While more studies of the long-term effects of the drugs are needed, some data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes. (wikipedia.org)
  • You can also visit the Food and Drug Administration (FDA) website ( http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm ) to obtain the interferon beta-1a Medication Guide. (medlineplus.gov)
  • 5 drug groups), cancer (14 drugs) and multiple sclerosis (2 drugs). (who.int)
  • In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. (sciencedaily.com)
  • Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). (sciencedaily.com)
  • Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. (sciencedaily.com)
  • The diagnostic criteria for multiple sclerosis have evolved over time and currently the 2010 McDonald criteria are the most widely accepted. (rcpe.ac.uk)
  • PARADIGMS Study Group 2018, ' Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis ', New England Journal of Medicine , vol. 379, no. 11, pp. 1017-1027. (elsevierpure.com)
  • FINDINGS: 41 (31%) of 131 patients on interferon beta-1a and 62 (47%) of 132 on placebo converted to clinically definite multiple sclerosis (odds ratio 0.52 [95% CI 0.31-0.86], p=0.0115). (ox.ac.uk)
  • INTERPRETATION: Early treatment with interferon beta-1a is effective in reducing conversion to clinically definite multiple sclerosis and in slowing progressive loss of brain tissue in patients with clinically isolated syndromes. (ox.ac.uk)
  • UNLABELLED: INTRODUCTION: With the increasing use of recombinant α and β interferon therapy for the treatment of various disorders, cases of interferon-associated sarcoidosis have been reported in the literature. (ox.ac.uk)
  • Overall, therapy with interferon beta leads to a reduction of neuron inflammation. (wikipedia.org)
  • The effect of interferon beta (IFNB) therapy on expression was evaluated. (edu.au)
  • If the diagnosis is confirmed, patients should be treated immediately (with plasma exchange if necessary) and interferon beta therapy discontinued. (mims.co.uk)
  • Gene therapy-induced antigen-specific Tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis. (benthamscience.com)
  • Soluble interleukin 23 receptor gene therapy with adeno-associated vectors for the treatment of multiple sclerosis. (benthamscience.com)
  • Hamana A, Takahashi Y, Tanioka A, Nishikawa M, Takakura Y. Safe and effective interferon-beta gene therapy for the treatment of multiple sclerosis by regulating biological activity through the design of interferon-beta-galectin-9 fusion proteins. (benthamscience.com)
  • as a novel combined immune gene therapy for Multiple Sclerosis disease. (benthamscience.com)
  • The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequent administration than available treatments. (qxmd.com)
  • Interferon beta-1a, currently in use to treat multiple sclerosis , and interferon alfa-2b are both under investigation as potential treatments for people with COVID-19 coronavirus disease, the deadly respiratory pandemic caused by the SARS -nCoV-2 virus. (hdkino.org)
  • This case illustrates that interferons not only cause local but also systemic adverse events of the skin. (uni-wuerzburg.de)
  • These systemic side effects might indicate that the Th17/IL-17 axis plays a prominent role in the immunopathogenesis of this individual case and that the autoimmune process might be deteriorated by further administration of interferons. (uni-wuerzburg.de)
  • Graves' disease (GD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are all typical autoimmune diseases. (frontiersin.org)
  • Intermediate uveitis may be initially associated with the development of a systemic disease, such as multiple sclerosis (MS) or sarcoidosis. (medscape.com)
  • Interferons modulate the response of the immune system to viruses , bacteria, cancer , and other foreign substances that invade the body. (hdkino.org)
  • Because the exact antigen or target of the immune-mediated attack is not known, many experts prefer to label multiple sclerosis as 'immune-mediated instead of an autoimmune disease. (medicinenet.com)
  • B cells are thought to influence the underlying pathogenesis of multiple sclerosis by means of antigen presentation, autoantibody production, cytokine regulation, and the formation of ectopic lymphoid aggregates in the meninges, which possibly contribute to cortical demyelination and neurodegeneration. (synergy-munich.de)
  • Interferons are thought to alter response to surface antigen and may enhance immune cell activities. (medscape.com)
  • More recent data suggest that interferon betas does not hasten disability. (wikipedia.org)
  • Multiple sclerosis is a leading cause of disability in young adults, with the Scottish population suffering the highest prevalence in Europe. (rcpe.ac.uk)
  • Serious adverse events occurred in 7 patients (6.5%) in the interferon beta-1a group and included infection (in 2 patients) and supraventricular tachycardia (in 1 patient). (elsevierpure.com)
  • Any suspected adverse reactions to interferon beta should continue to be reported via the Yellow Card scheme . (mims.co.uk)
  • METHODS: MRI data for brain volume measurements at baseline, month 12, and month 24 were available from 131, 111, and 112 patients assigned treatment (22 microg interferon beta-1a), and 132, 98, and 99 patients assigned placebo respectively. (ox.ac.uk)